Denali Therapeutics - DNLI EV/EBITDA Multiple
Backed by industry behemoths, Denali Therapeutics (DNLI) avoids price wars during its trial periods. Future revenue is based on the commercialization of therapies to combat Alzheimer's and Parkinson's. This chart from the GURU.Markets platform illustrates the company's EV/EBITDA ratio over a time series with a metric value of 0.00, reflecting the financial potential of developing innovative drugs for neurodegeneration.
Comprehensive metric breakdowns and analytics for denalitherapeutics.com (DNLI)
- market price and analyst price targets:
- issuer market value details:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Denali Therapeutics|DNLI - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Denali Therapeutics Inc.|DNLI - Company Cumulative Indebtedness|Debts to Book Capitalization Denali Corp|DNLI - Company Long-Term Loans and Borrowings|Company Short-Term Debts Denali Therapeutics|Quick Liquidity denalitherapeutics.com
- business earnings and investment ratios data:
DNLI - Final Profit|Projected Future Earnings Denali Therapeutics|DNLI - P/E Multiple|Future Price to Earnings Denali Therapeutics|DNLI - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Denali Corp|DNLI - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Denali Therapeutics|DNLI - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months denalitherapeutics.com|DNLI - Net earnings per one share growth for the current year|Earnings growth forecast for next year Denali Therapeutics
General company analysis:Denali Therapeutics Inc DNLI
Developing technologies to cross the blood-brain barrier requires colossal investments, which, in the absence of stable sales, blocks the operating leverage of Denali Therapeutics (DNLI). An analysis of the EV/EBITDA metric for this capital-intensive business with a value of 0.00 links the enterprise value to its ability to generate earnings before interest and taxes, warning investors of capital freeze risks if critical historical levels are exceeded.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|NBIX: Enterprise Value to Operating Income Before Depreciation|Regencell Bioscience - EV/EBITDA Multiple|AXSM - EV/EBITDA Multiple|ACADIA Pharmaceuticals Inc. (ACAD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XENE (Xenon Pharmaceuticals Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VKTX (Viking Pharma) - EV/EBITDA Multiple|Supernus Corp (SUPN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|HRMY (harmonybiosciences.com) - Business Value to Operating Income Before Depreciation|Biohaven - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio AMLX (Amylyx Pharmaceuticals Inc)|Trevi Pharma - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation PRAX (Praxis Corp)|AVXL: EV/EBITDA Multiple|Company Value to EBITDA ceribell.com (CBLL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prothena Corporation plc|ALEC: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANNX|EV/EBITDA Multiple omeros.com (OMER)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Neurogene Inc. NGNE|ACIU (acimmune.com) - Company Value to Operating Income Before Depreciation Ratio|Voyager Therapeutics, Inc. - EV/EBITDA Multiple|Company Value to EBITDA Neumora|SCLX (Scilex Holding Co.) - Enterprise Value to EBITDA Ratio|Tevogen Bio Inc. (TVGN) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio ACOG|CGTX (cogrx.com) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple IKT|Total Company Value to Operating Income Before Depreciation Ratio Cassava Sciences Inc|EV/EBITDA Multiple ASRT (Assertio)|COYA - Enterprise Value to EBITDA Ratio|VTGN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Ovid Therapeutics Inc. OVID|ABOS: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation CRVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alterity Therapeutics Ltd.|Enterprise Value to Operating Income Before Depreciation CLNN (Clene Nanomedicine)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PepGen Inc. (PEPG)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization JUNS (jupiterneurosciences.com)|EV/EBITDA Multiple RLMD (Relmada Therapeutics, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Annovis Bio Inc (ANVS)|GRCE - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AIFF (Firefly Neuro) - Enterprise Value to Operating Income Before Depreciation|KLTO: EV/EBITDA Multiple|Company Value to EBITDA NeuroSense Therapeutics Ltd. (NRSN)|Enterprise Value to EBITDA Ratio RVPH|EV/EBITDA Multiple MetaVia, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|HSDT (heliusmedical.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio PASG|Neuphoria Therapeutics, Inc. (NEUP) - Company Value to EBITDA|Minerva Neurosciences, Inc. - EV/EBITDA Multiple|ATHA (Athira Pharma Inc) - Enterprise Value to Operating Income Before Depreciation|ADXN: EV/EBITDA Multiple|Company Value to EBITDA Alzamend Neuro (ALZN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|Enterprise Value to Operating Income Before Depreciation PTIX (Protagenic)|EV/EBITDA Multiple KTTA|EV/EBITDA Multiple cortigent.com (CRGT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avenue Therapeutics, Inc ATXI|BrainStorm Cell Therapeutics Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Cara Therapeutics, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio chromocell.com CHRO|ELYM (eliemtx.com) - Enterprise Value to EBITDA Ratio|Intra-Cellular Therapies, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio LBPH|MRNS (Marinus Pharma) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple NKGN|NRBO (neurobopharma.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SAGE (Sage Therapeutics)|Synaptogenix Inc. (SNPX) - Company Value to EBITDA|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation VIGL (Vigil Neuroscience)|WENA: EV/EBITDA Multiple|cerevel.com (CERE) - EV/EBITDA Multiple
